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Type 2 diabetes and prediabetes are established risk factors for atherosclerosis. The aim of
this study was to evaluate the atherosclerotic plaque burden in the carotid arteries of
patients with acute coronary syndrome according to their glycemic status.
Methods
Patients with acute coronary syndrome and no previous history of type 2 diabetes were con-
secutively included in the study. Glucose metabolism was evaluated with fasting glucose in
plasma, HbA1c and a standard two-hour oral glucose tolerance test. Atherosclerotic plaque
in the carotid arteries was evaluated with a standardized ultrasound examination where total
plaque area was measured and patients classified as having no plaque or a significant pla-
que formation.
Results
A total of 245 acute coronary syndrome patients (male 78%, 64 years (SD: 10.9)) were
included. The proportion diagnosed with normal glucose metabolism, prediabetes and type
2 diabetes was 28.6%, 64.1% and 7.3%, respectively. A significant atherosclerotic plaque
was found in 48.5%, 66.9% and 72.2% of patients with normal glucose metabolism, predia-
betes and type 2 diabetes, respectively. An incremental increase in total plaque area was
found from normal glucose metabolism to prediabetes (25.5%) and from normal glucose
metabolism to type 2 diabetes (35.9%) (p = 0.04). When adjusted for conventional cardio-
vascular risk factors the OR of having significant atherosclerotic plaque in the carotid arter-
ies was 2.17 (95% CI 1.15–4.15) for patients with newly diagnosed dysglycemia compared
to patients with normal glucose metabolism. When additionally adjusted for the 2-hour
plasma glucose after glucose loading (2hPG) the OR attenuated to 1.77 (95% CI 0.83–
3.84).
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Conclusion
Newly detected dysglycemia is an independent predictor of significant atherosclerotic pla-
que in the carotid arteries with oral glucose tolerance test as a major determinant of carotid
plaque burden in this group of individuals with acute coronary syndrome.
Introduction
Type 2 diabetes mellitus (T2DM) and prediabetes are established risk factors for atherosclero-
sis and cardiovascular disease (CVD) and associated with increased mortality compared to
those with normal glucose metabolism (NGM) [1]. Patients with acute coronary syndromes
(ACS) have a high prevalence of undiagnosed T2DM and prediabetes [2, 3] at hospital admis-
sion. There is evidence that myocardial damage may already be present at the time of clinical
diagnosis of T2DM indicating that the dysglycemia (T2DM or prediabetes) has remained
undiagnosed for months or years [4]. Moreover, studies have indicated that newly diagnosed
dysglycemia in patients with myocardial infarction is a major risk factor for future cardiovas-
cular events [5, 6]. It therefore has been recommended to screen for metabolic derangements
in patients admitted to hospital for ACS [7].
Atherosclerotic disease in the carotid arteries has been associated with coronary artery dis-
ease and is an indicator of an increased atherosclerotic burden [8]. Measuring total plaque
area (TPA) in the carotid arteries is a noninvasive method to quantify atherosclerotic burden.
Carotid plaque is also an independent predictor of CVD and improves risk stratification in
addition to traditional risk factors for CVD [9, 10].
We hypothesized that patients with ACS have a high prevalence of atherosclerotic plaque in
the carotid arteries and that ACS patients with newly diagnosed T2DM and prediabetes have
increased atherosclerotic burden compared to ACS patients with NGM. Therefore, we set out
to evaluate the atherosclerotic plaque burden in the carotid arteries of patients with ACS and
related the plaque burden to newly detected metabolic derangements.
Methods
Study population
Patients admitted to the coronary care unit of Landspitali, the University Hospital of Iceland
with the diagnosis of ACS were consecutively included in the study between June 2013 to
October 2014. ACS was defined according to the joint European Society of Cardiology (ESC)
and American College of Cardiology recommendations [11]. Patients with previously known
T2DM, cognitive dysfunction, living in a nursing home or outside the catchment area of the
hospital were excluded from the study.
Prior to any study related procedure informed written consent was obtained for each par-
ticipant. The study protocol adhered to the principles laid out in the Declaration of Helsinki
[12] and was approved by the Icelandic Bioethics Committee (VSN: 13-069-S1). Information
on prespecified demographic, personal, medication and lifestyle data were obtained from
patients during admission and from hospital records. Patients with previous history of hyper-
tension or on blood pressure lowering medication were classified as having hypertension.
Likewise, patients with previous history of hypercholesterolemia or on statins were classified
as hypercholesterolemia. Patients with 1st degree family members with coronary artery disease
(CAD) were defined as having family history of CAD.
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Diagnosis of glucose metabolism
Glucose metabolism was evaluated after an overnight fast of at least ten hours with fasting
plasma glucose (FPG), glycated hemoglobin (HbA1c) and a standard oral glucose tolerance
test (OGTT). Two hours after ingesting a solution containing 75 g of glucose measurements of
plasma glucose (2hPG) were made. Measurements of glucose metabolism were made during
hospitalization, generally on third to fifth day after admission, and repeated at least three
months later. All samples collected for venous plasma glucose measurements were centrifuged
and analyzed immediately after blood collection. Glucose levels were determined using re-
agents, calibrators and Vitros 250/950 analyzers from Ortho Clinical Diagnostics, Rochester,
USA and HbA1c levels were determined using reagents, calibrators and Cobas c311 analyzer
from Roche, Mannheim, Germany.
The classification of glucose metabolism was based on the American Diabetes Association
(ADA) criteria, where prediabetes was defined as HbA1c 5.7–6.4% (39–47 mmol/mol), FPG
5.6–6.9 mmol/l (100–125 mg/dL) or 2hPG 7.8–11.0 mmol/l (140–199 mg/dL) and T2DM as
HbA1c6.5% (48 mmol/mol), FPG7.0 mmol/l (126 mg/dL) or 2hPG11.1 mmol/l (200
mg/dL) [13]. Patients were classified as having T2DM if at least two measurements were above
the cut-point for T2DM according to the ADA criteria while patients with one measurement
above the cut-point of T2DM or at least one measurement above the cut-point for prediabetes
were classified as having prediabetes.
Carotid imaging
Three months after discharge an ultrasound imaging of the carotids was performed according
to a standardized protocol [14]. A Toshiba Aplio 300 system with a two-dimensional 6.8 MHz
linear array transducer was used for all ultrasound imaging by a trained sonographer. Stan-
dardized longitudinal B-mode images of the common carotid artery, bifurcation and internal
carotid artery from the near and far wall in the left and right carotid arteries were examined.
The lateral extent of the common carotid segment was defined relative to the tip of the flow
divider, which is normally the most clearly defined anatomical reference in the proximity of
the carotid bifurcation. The bifurcation and internal carotid segments were also defined by
using the tip of the flow divider. The segments were defined as: the near wall and far wall of
the arterial segment extending from 10 mm to 20 mm proximal to the tip of the flow divider
into the common carotid artery (CCA); the near wall and far wall of the carotid bifurcation
beginning at the tip of the flow divider and extending 10 mm proximal to the flow divider tip
(BIF); and the near wall and far wall of the proximal 10 mm of the internal carotid artery
(ICA). Images for the assessment of the carotid intima-media thickness (cIMT) were acquired
from the predefined 10 mm segment of each CCA at defined interrogation angles using the
Meijers arc [15] and standard images obtained from four angels at each site. The mean cIMT
of the near and far walls were determined from a single image at each interrogation for both
CCA and the mean cIMT values from these sites comprised the cIMT outcome parameter.
Atherosclerotic plaques in the carotid artery segments (BIF and ICA) extending 10 mm
proximal and distal from the tip of the flow divider, were categorized as a significant or not.
The most severe lesion per segment was assessed [16]. Patients with a least one, clear, reason-
able easy to be visualized plaque with intima media thickness of at least twice the thickness of
adjacent sites causing at least some diameter reduction of the vessel lumen were classified as
having significant plaque. In addition, the Artery Measurements System software (v.2.02.) was
used to assess quantitatively the plaque area of all visible plaques in the BIF and ICA segments.
An atherosclerotic plaque was defined by an isolated thickening at least double the adjacent
normal cIMT by visual assessment. The plaque boundaries were traced with a cursor on the
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computer screen and the area (mm2) for each plaque automatically computed by the program.
The TPA was calculated by summing the area of all individual plaques. Acquisition and inter-
pretations were made by trained sonographers [14].
Severity of coronary atherosclerosis
All patients underwent coronary angiography during admission. Coronary arteries with
lumen reduction of more than 70% were considered to have a significant stenosis and patients
classified of having 0-, 1-, 2- or 3-vessel disease. Gensini score was applied to evaluate the coro-
nary artery disease by the degree of lumen reduction and the importance of the lesion´s loca-
tion [17].
Statistical analysis
Categorical variables were presented as percentage. Normally distributed continuous variables
were presented as means (standard deviation, SD), otherwise as median with interquartile range
(IQR). Between group comparison of NGM, prediabetes and T2DM was made using the chi-
square test and analysis of variance or Kruskal Wallis test for categorical and continuous vari-
ables, respectively. The odds ratio (OR) of having significant plaque in the carotid arteries was
estimated with a multivariable logistic regression model. The predictors used were HbA1c, FPG
and 2hPG. The association between TPA and risk factors for atherosclerosis was evaluated with
general linear regression models, both unadjusted and adjusted for glucometabolic factors and
conventional atherosclerotic risk factors: age, gender, hypertension, hypercholesterolemia,
smoking status and BMI. The level of statistical significance was set at p<0.05. All statistical
analyses were performed using the R software version 3.2.2. [18]
Results
A total of 435 patients admitted to the coronary care unit with the diagnosis of ACS were con-
sidered for inclusion in the study. Among these, 90 were discharged before the OGTT could
be performed, 60 refused participation and two died shortly after admission. Therefore, 283
patients were included in the study shortly after admission. Before the follow-up visit at 3
months, 21 patients were lost to follow-up, 13 patients withdrew consent, three died and one
had a stroke. The remaining 245 patients comprised the study population.
The baseline characteristics of the study population are presented in Table 1. The mean age
was 64.0 (SD 10.9) years, 78.0% were male and all participants in the study were Caucasian of
European origin. A total of 28.6%, 64.1% and 7.3% were diagnosed with NGM, prediabetes
and T2DM, respectively. The mean TPA and cIMT in the study population was 103.3 mm2
(SD 64.7) and 0.90 mm (SD 0.15), respectively.
At least one atherosclerotic plaque was detected in 48.5%, 66.9% and 72.2% of patients with
NGM, prediabetes and T2DM, respectively (Table 2). A significant difference in TPA was
found between patients diagnosed with NGM (86.8 mm2 (SD 57.2)) prediabetes (108.9 mm2
(SD 66.1)) and T2DM (118.0 mm2 (SD 70.7)) (p<0.04). The incremental increase in TPA was
25.5% and 35.9% among patients diagnosed with prediabetes and T2DM, respectively, com-
pared to patients with NGM. A significant difference in BMI, waist-to-hip ratio, smoking sta-
tus, high-sensitivity C-reactive protein (hS-CRP), insulin resistance (HOMA-IR), number of
diseased coronary arteries and Gensini score was found between different glucose metabolism
categories (Table 2). Increased TPA was detected among patients with impaired glucose toler-
ance (IGT), either alone or in combination with impaired fasting glucose (IFG), compared
with patients with isolated IFG (Table 3). No difference was detected in cIMT between patients
with different glucose metabolism categories while an association with cIMT was found
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Table 1. Baseline characteristics.
(n = 245)
Age, years (SD) 64.0 (10.9)
Gender
- Male 191 (78%)
- Female 54 (22%)
Glucose metabolism
- At admission:
HbA1c, % (SD) 5.4 (0.5)
FPG, mmol/l (SD) 5.3 (0.9)
2hPG, mmol/l (SD) 7.8 (2.6)
- At follow-up:
HbA1c, % (SD) 5.5 (0.4)
FPG, mmol/l (SD) 5.5 (0.8)
2hPG, mmol/l (SD) 6.7 (2.6)
hs-CRP, mg/L (IQR) 1.1 (0.6, 2.3)
Insulin, mU/L (SD) 12.8 (8.6)
HOMA-IR (SD) 3.2 (2.4)
TPA, mm2 (SD) 103.3 (64.7)
Grey-scale median (SD) 37 (10)
Mean cIMT, mm (SD) 0.90 (0.15)
Carotid plaque
- No plaque 93 (38.0%)
- Significant plaque 152 (62.0%)
BMI, kg/m2 (SD) 28.7 (4.2)









SBP, mmHg (SD) 139 (22)










Gensini score (SD) 40.4 (34.6)
SD: standard deviation, FPG: fasting plasma glucose, 2hPG: 2-hour plasma glucose, hs-CRP: high-
sensitivity C-reactive protein, IQR: interquartile range, HOMA-IR: homeostatic model assessment insulin
resistance, TPA: total plaque area, cIMT: carotid intima-media thickness, BMI: body mass index, WHR:
waist to hip ratio, FH: family history, CAD: coronary artery disease, SBP: systolic blood pressure, DBP:
diastolic blood pressure, ACS: acute coronary syndrome, UAP: unstable angina pectoris, NSTEMI: non-ST
elevation myocardial infarct, STEMI: ST elevation myocardial infarct
aCAD with 1st degree family member
b70% of lumen reduction
https://doi.org/10.1371/journal.pone.0183839.t001
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Table 2. Pertinent characteristics of patients divided according to their glucose metabolism.
NGM (n = 70) Prediabetes (n = 157) DM (n = 18) p-value
Age, years (SD) 64.0 (12.0) 63.9 (10.2) 65.0 (12.5) 0.92
Gender 0.54
- Male 57 (81.4%) 119 (75.8%) 15 (83.3%)
- Female 13 (18.6%) 38 (24.2%) 3 (16.7%)
Glucose metabolism
- At admission:
HbA1c, % (SD) 5.1 (0.4) 5.4 (0.3) 6.5 (1.0) <0.01
FPG, mmol/l (SD) 4.8 (0.4) 5.3 (0.6) 7.0 (1.5) <0.01
2hPG, mmol/l (SD) 6.3 (0.9) 7.9 (2.1) 13.3 (3.3) <0.01
- At follow-up:
HbA1c, % (SD) 5.2 (0.3) 5.5 (0.4) 6.1 (0.5) <0.01
FPG, mmol/l (SD) 5.0 (0.4) 5.6 (0.5) 7.1 (1.4) <0.01
2hPG, mmol/l (SD) 5.1 (1.0) 6.8 (2.3) 11.9 (3.2) <0.01
hs-CRP, mg/L median (IQR) 0.7 (0.5, 1.3) 1.4 (0.7, 2.7) 1.4 (0.9, 1.4) <0.01
Insulin, mU/L (SD) 10.47 (6.58) 13.51 (8.90) 16.42 (11.11) 0.07
HOMA-IR, units (SD) 2.33 (1.56) 3.40 (2.41) 4.96 (3.86) <0.01
TPA, mm2 (SD) 86.8 (57.2) 108.9 (66.1) 118.0 (70.7) 0.04
Grey-scale median (SD) 38 (11) 36 (10) 36 (11) 0.69
Mean cIMT, mm (SD) 0.87 (0.15) 0.91 (0.14) 0.90 (0.15) 0.28
Carotid plaque 0.13
- No plaque 36 (51.5%) 52 (33.1%) 5 (27.8%)
- Significant plaque 34 (48.5%) 105 (66.9%) 13 (72.2%)
BMI, kg/m2 (SD) 27.8 (4.0) 28.8 (4.1) 31.4 (4.8) <0.01
WHR (SD) 0.96 (0.07) 0.98 (0.08) 1.01 (0.06) 0.02
Smoking status: 0.03
- Never 44.3% 28.0% 22.2%
- Previous 44.3% 44.0% 44.5%
- Current 11.4% 28.0% 33.3%
FH of CADa 67.1% 64.3% 72.2% 0.78
Hypercholesterolemia 48.6% 43.9% 55.6% 0.54
Hypertension 52.9% 57.3% 66.7% 0.60
Previous CAD 35.7% 30.6% 50.0% 0.22
SBP, mmHg (SD) 139 (22) 139 (23) 137 (18) 0.93
DBP, mmHg (SD) 77 (12) 78 (13) 75 (12) 0.71
ACS 0.57
- UAP 31.4% 28.7% 38.9%
- NSTEMI 45.7% 38.9% 33.3%
- STEMI 22.9% 32.4% 27.8%
CADb 0.03
- 0-vessel 10.8% 7.1% 0%
- 1-vessel 50.0% 35.4% 33.3%
- 2-vessel 19.6% 37.0% 27.8%
- 3-vessel 19.6% 20.5% 38.9%
Gensini score (SD) 38.2 (37.5) 39.1 (32.4) 60.0 (36.3) 0.04
NGM: normal glucose metabolism, T2DM: type 2 diabetes mellitus, SD: standard deviation, FPG: fasting plasma glucose, 2hPG: 2-hour plasma glucose,
hs-CRP: high-sensitivity C-reactive protein, IQR: interquartile range, HOMA-IR: homeostatic model assessment insulin resistance, TPA: total plaque area,
cIMT: carotid intima-media thickness, BMI: body mass index, WHR: waist to hip ratio, FH: family history, CAD: coronary artery disease, SBP: systolic blood
pressure, DBP: diastolic blood pressure, ACS: acute coronary syndrome, UAP: unstable angina pectoris, NSTEMI: non-ST elevation myocardial infarct,
STEMI: ST elevation myocardial infarct
aCAD with 1st degree family member
b70% of lumen reduction
https://doi.org/10.1371/journal.pone.0183839.t002
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between different age categories (per 5 years) and gender, 0.030 mm (SE; 0.004, p<0.01) and
0.057 mm (SE; 0.022, p = 0.01), respectively.
When the relationship between the different glucometabolic assessments and carotid pla-
que were examined, only the 2hPG during admission and at follow-up showed statistically sig-
nificant unadjusted OR of having significant plaque in the carotid arteries, being 2.37 (95% CI
1.36–4.18) and 2.25 (1.21–4.35), respectively. For HbA1c and FPG classification of dysglyce-
mia the unadjusted OR for the detection of atherosclerotic plaque in the carotids did not reach
statistical significance (Table 4A).
When adjusted for conventional atherosclerotic risk factors, the OR for patients diagnosed
with dysglycemia according to the 2hPG during admission of having significant plaque in the
carotid arteries was 1.92 (95% CI 1.05–3.55) and 1.51 (0.74–3.18) at follow-up. However, the
ORs for HbA1c and FPG remained statistically non significant.
Table 3. Carotid plaque burden among patients with IFG, IGT and combination of IFG and IGT.
IFG (n = 50) IGT (n = 42) IFG & IGT (n = 52) p-value
TPA, mm2 (SD) 87.8 (53.1) 127.4 (70.4) 123.1 (70.9) <0.01
Mean cIMT, mm (SD) 0.88 (0.16) 0.91 (0.13) 0.92 (0.13) 0.30
Carotid plaque 0.67
- No plaque 36.0% 28.6% 28.8%
- Significant plaque 64.0% 71.4% 71.2%
IFG: impaired fasting glucose, IGT: impaired glucose tolerance, SD: standard deviation, TPA: total plaque area, cIMT: carotid intima-media thickness.
https://doi.org/10.1371/journal.pone.0183839.t003
Table 4. Carotid plaque burden by different glucose methods.
a) The OR of having significant plaque in the carotid arteries of patients diagnosed with dysglycemia based on different glucometabolic assessments
compared to normal glucose level.
Unadjusted OR, (95% CI) p-value aAdjusted OR, (95% CI) p-value
HbA1c
- Dysglycemia during admission 1.31 (0.69–2.57) 0.41 0.89 (0.44–1.93) 0.74
- Dysglycemia at follow-up 1.74 (0.96–3.27) 0.07 1.58 (0.82–3.13) 0.18
FPG
- Dysglycemia during admission 1.46 (0.80–2.76) 0.23 1.52 (0.77–3.08) 0.24
- Dysglycemia at follow-up 1.44 (0.85–2.46) 0.18 1.61 (0.89–2.96) 0.12
2hPG
- Dysglycemia during admission 2.37 (1.36–4.18) <0.01 1.92 (1.05–3.55) 0.04
- Dysglycemia at follow-up 2.25 (1.21–4.35) 0.01 1.51 (0.74–3.18) 0.26
b) Difference in TPA among patients diagnosed with dysglycemia based on different glucometabolic assessment compared to normal glucose level.
Unadjusted Estimate (SE) p-value aAdjusted Estimate (SE) p-value
HbA1c
- Dysglycemia during admission 27.3 (10.3) <0.01 15.1 (9.4) 0.11
- Dysglycemia at follow-up 14.5 (9.4) 0.12 13.2 (8.5) 0.12
FPG
- Dysglycemia during admission 6.3 (9.8) 0.52 7.3 (8.9) 0.41
- Dysglycemia at follow-up 1.67 (8.5) 0.84 6.9 (7.8) 0.38
2hPG
- Dysglycemia during admission 35.0 (8.3) <0.01 25.5 (7.6) <0.01
- Dysglycemia at follow-up 37.0 (9.2) <0.01 24.0 (8.8) <0.01
OR: odds-ratio, CI: confidence interval, SE: standard error, 2hPG: 2-hour plasma glucose, FPG: fasting plasma glucose.
aAdjusted for age, gender, hypertension, hypercholesterolemia, smoking status, and BMI
https://doi.org/10.1371/journal.pone.0183839.t004
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The relationship between the diagnosis of dysglycemia by the three different methods and
TPA is shown in Table 4B. Only 2hPG showed a statistically significant association with TPA
both during admission and follow up. HbA1c during admission was associated with an increase
in mean TPA but was not statistically significant at the follow up. Based on the multiple regression
model, after adjusting for conventional atherosclerotic risk factors, TPA was significantly associ-
ated with 2hPG during admission and at follow-up with 25.5 mm2 (SE 7.6, p<0.01) and 24.0
mm2 (SE 8.8, p<0.01) greater TPA, respectively, compared to those with normal glucose level.
The unadjusted OR of patients diagnosed with prediabetes, T2DM and dysglycemia of hav-
ing significant atherosclerotic plaque in their carotid arteries compared to patients with NGM
was 2.14 (95% CI; 1.21–3.81), 2.75 (95% CI; 0.93–9.34) and 2.19 (95% CI; 1.25–3.87), respec-
tively (Table 5A, model 1).
From the multiple logistic regression analysis after adjusting for conventional atheroscle-
rotic risk factors the ORs of having significant atherosclerotic plaque for patients diagnosed
with prediabetes, T2DM and dysglycemia (determined by abnormal results in either 2hPG,
HbA1C or FPG) compared to NGM was 2.14 (95% CI 1.13–4.12), 2.50 (0.75–9.51) and 2.17
(95% CI 1.15–4.15), respectively (Table 5A, model 2). To examine if any of the dysglycemic
metabolic determinants might explain this association we additionally adjusted for 2hPG,
HbA1C and fasting glucose both during admission and at follow-up. When adjusted for 2hPG
the statistical significance of the ORs for patients diagnosed with prediabetes and dysglycemia
of having significant atherosclerotic plaque compared to NGM was lost and became 1.78 (95%
CI 0.83–3.88) and 1.77 (95% CI 0.83–3.84), respectively (Table 5A, model 3). When adjusted
for FPG during admission and at follow-up the ORs were also attenuated 1.94 (95% CI 0.89–
4.29) and 1.93 (95% CI 0.89–4.27) for prediabetes and dysglycemia respectively, but remained
significant when adjusted for HbA1c during admission and at follow-up.
Based on regression analysis, the diagnosis of prediabetes, T2DM and dysglycemia was as-
sociated with an increase in TPA of 22.1 mm2 (SE: 9.3, p = 0.02), 31.2 mm2 (SE: 17.0, p = 0.07)
and 23.0 mm2 (SE 9.2, p = 0.01), respectively, compared to patients with NGM (Table 5B, model
1). From the multiple variable regression model after adjusting for conventional atherosclerotic
risk factors a significant increase in TPA was associated with the diagnosis of prediabetes and
Table 5. Glucose metabolic derangements and carotid plaque burden.
a) The OR of having significant plaque in the carotid arteries among patients diagnosed with prediabetes, T2DM or dysglycemia defined as any of
abnormal 2hPG, HbA1C and fasting glucose.
Model 1 Model 2 Model 3





Prediabetes 2.14 (1.21–3.81) 0.01 2.14 (1.13–4.12) 0.02 1.78 (0.83–3.88) 0.14
T2DM 2.75 (0.93–9.34) 0.08 2.50 (0.75–9.51) 0.15 2.18 (0.44–12.03) 0.35
Dysglycemia 2.19 (1.25–3.87) <0.01 2.17 (1.15–4.15) 0.02 1.77 (0.83–3.84) 0.14
b) Difference in TPA among patients diagnosed with prediabetes, T2DM and dysglycemia defined as any of abnormal 2hPG, HbA1C and fasting glucose.
Model 1 Model 2 Model 3
Unadjusted Estimate mm2 (SE) p-value aAdjusted Estimate mm2 (SE) p-value bAdjusted Estimate mm2 (SE) p-value
Prediabetes 22.1 (9.3) 0.02 22.5 (8.5) <0.01 9.6 (9.9) 0.34
T2DM 31.2 (17.0) 0.07 29.4 (15.5) 0.06 1.1 (19.5) 0.95
Dysglycemia 23.0 (9.2) 0.01 23.1 (8.4) <0.01 10.0 (10.0) 0.32
OR: odds ratio, CI: confidence interval, SE: standard deviation, T2DM: type 2 diabetes mellitus
aAdjusted for age, gender, hypertension, hypercholesterolemia, smoking status, and BMI
b Adjusted for age, gender, hypertension, hypercholesterolemia, smoking status, BMI and 2hPG during admission and at follow-up
https://doi.org/10.1371/journal.pone.0183839.t005
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dysglycemia (Table 5B, model 2). When additionally adjusted for 2hPG during admission the dif-
ference in TPA among patients with prediabetes and dysglycemia was attenuated to 9.6 mm2 (SE:
10.0, p = 0.34) and 10.0 mm2 (SE 10.0, p = 0.32), respectively, compared to patients with NGM
(Table 5B, model 3) which is a reduction of the effect sizes by 57.3% and 56.7% for prediabetes
and dysglycemia, respectively. When adjusted independently for FPG and HbA1c during admis-
sion and at follow-up the difference in TPA among patients diagnosed with prediabetes and dys-
glycemia still remained statistically significant.
Discussion
In the current study, a high prevalence of atherosclerotic plaque in the carotid arteries was
detected with incremental increase in TPA in ACS patients diagnosed with prediabetes and
T2DM compared to patients with NGM. Detection of dysglycemia by measurement of 2hPG
rather than FPG or HbA1c identified increased risk of significant atherosclerotic plaque and
increased TPA. Therefore, newly detected glucose derangements are associated with increased
atherosclerotic burden in ACS patients.
All patients in the present study had established atherosclerotic disease in their coronary
arteries. Therefore it was expected to detect a high prevalence of atherosclerotic plaque in the
carotids in the study population. In this study the prevalence for significant atherosclerotic pla-
que was 62% compared to 10% reported from a general population study in Iceland that used
the same ultrasound protocol as in the current study [16]. When compared to an age- and gen-
der-matched control group from that population study the prevalence of significant plaque was
20% and mean TPA 39.1 mm2 compared to 103.3 mm2 in the present study. This highlights the
high atherosclerotic burden found in patients with CVD compared to the general population.
When the individual glucose measurement methods were evaluated separately the 2hPG
for dysglycemia during admission and at follow-up were found to be independent predictors
of having significant atherosclerotic plaque in the carotid arteries. Likewise, patients diagnosed
with dysglycemia on the 2hPG had significantly increased TPA compared to patients with
NGM. The 2hPG identifies patients who are nearly or completely insulin resistant, a condition
where the liver and muscles require more insulin to suppress the hepatic glucose production
and glucose uptake, respectively, that results in postprandial hyperglycemia [19, 20]. While the
pancreatic β-cells are able to increase their insulin production and secretion, causing hyperin-
sulinemia, the glucose tolerance remains normal. In time, however, the postprandial glucose
levels and subsequently the FPG levels rises due to increased insulin resistance and failure of
the β-cells to produce insulin, leading to overt T2DM [21].
Prediabetes and dysglycemia were found to be independent predictors of having significant
atherosclerotic plaque in the carotid arteries. A significant association was also detected
between TPA and metabolic derangements whether defined as prediabetes or dysglycemia. No
significant association was found between T2DM and TPA but there was a clear trend in that
direction. After being adjusted for conventional CVD risk factors the association between dys-
glycemia and TPA remained significant. However, when additionally adjusting for different
glucose metabolic measurements the 2hPG had a greater effect on the relationship between
dysglycemia and TPA as well as the OR of having significant plaque compared to FPG and
HbA1c. This indicates that among the three methods of glucometabolic measurement 2hPG
has the strongest relation to atherosclerosis development in this group of patients with ACS.
The 2hPG, based on the OGTT, had stronger association with increased TPA and signifi-
cant plaque in the carotid arteries than either FPG or HbA1c.
Elevated 2hPG is an indicator of insulin resistance and hyperinsulinemia. Insulin resistance
and hyperinsulinemia have been suggested to cause vascular dysfunction and an increase in
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reactive oxygen species, which leads to vascular inflammation and proliferation of smooth
muscle cells that, in turn, accelerate the atherosclerotic process [22]. Also, postprandial hyper-
glycemia represents the highest blood glucose levels during the day and the greatest fluctua-
tions in glycaemia that could contribute to abnormal endothelial function [21]. Finally,
patients with postprandial hyperglycemia have higher prevalence of metabolic syndrome, with
central obesity, dyslipidemia and hypertension, which in itself increases risk for CVD [21].
Insulin resistance and hyperinsulinemia are conditions that are undetected for many years
that contribute to greater atherosclerotic disease and increased risk for CVD. Our results con-
cur with these findings in that 2hPG was found to have a stronger association with atheroscle-
rosis compared to FPG and HbA1c.
To our knowledge, this is the first study to evaluate TPA in patients with ACS in relation to
glucose metabolism classification. Increased TPA in patients newly diagnosed with prediabetes
and dysglycemia suggests that these patients have had undiagnosed dysglycemia for some time
before being admitted with ACS, causing accelerated atherosclerotic plaque formation and
perhaps leading to plaque instability and rupture which is a key process in the development of
ACS. Our results also support this assumption in that prediabetes and dysglycemia are shown
to be independents risk factors of having significant plaque on carotid ultrasound examina-
tion. These findings are in line with previous studies indicating a high proportion of undiag-
nosed dysglycemia in the general population and they underscore the importance of timely
preventive measures to enhance public health [23]. Patients who are diagnosed with dysglyce-
mia should receive lifestyle counselling, mainly improving diet and increased physical activity
to promote weight loss and lower cardiovascular risk [24]. Patients diagnosed with prediabetes
and T2DM could also be offered pharmacotherapy with metformin to reduce risk of develop-
ing T2DM and reduce risk of myocardial infarction, respectively [25, 26]. In addition, it has
been reported that reducing post-prandial hyperglycemia with acarbose, an alpha-glycosidase
inhibitor, can attenuate the progression of IMT in patients with IGT [27].
A limitation in the present study is a low prevalence of T2DM that is due to the strict diag-
nostic criteria applied for T2DM and a relatively low prevalence of T2DM in the general popu-
lation in Iceland compared to other western countries [28]. Due to this low prevalence the
power to detect significant association between T2DM and TPA is limited.
Conclusion
A high prevalence of atherosclerotic plaque in the carotid arteries was detected with incre-
mental increase in TPA in ACS patients diagnosed with prediabetes and T2DM compared to
patients with NGM. Patients diagnosed with dysglycemia according to the 2hPG were at
increased risk of significant atherosclerotic plaque in their carotid arteries and had signifi-
cantly increased TPA. The importance of the 2hPG in the risk stratification of these patients
is reflected by the fact that after adjustment for conventional risk factors and the 2hPG no
increased burden of atherosclerotic plaque remains, indicating the role of OGTT as a predictor
of increased carotid plaque burden. Thus newly detected metabolic derangements by screening
are an important indicator of accelerated atherosclerotic plaque formation in the ACS popula-
tion. Timely detection and treatment of dysglycemia might prove advantageous for the future
care in this high-risk population.
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